From owner-sci-resources@net.bio.net Mon Jul 05 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 4 July 1993 Message-ID: Date: 6 Jul 93 17:45:47 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 477 Approved: sci-resources-moderator@net.bio.net ** NEW DOCUMENTS ON STIS ** Document Type: Antarctic EAM Title: USAP environmental documents list File size (bytes): 12999 STIS Filename: opp93000 Title: Sanitary wastewater management, McMurdo File size (bytes): 46726 STIS Filename: opp93003 Title: Explosives in the Sirius program< File size (bytes): 1161 STIS Filename: opp93005 Title: Blasting for fill rock, McMurdo< File size (bytes): 9103 STIS Filename: opp93008 Title: Installation of runway-Pegasus File size (bytes): 7972 STIS Filename: opp93009 Title: Water under floor of laboratory File size (bytes): 10714 STIS Filename: opp93010 Title: Collection of earth fill, McMurdo File size (bytes): 3521 STIS Filename: opp93011 Title: Waste minimization, McMurdo File size (bytes): 3282 STIS Filename: opp93012 Title: Recovery of D-8 tracked vehicle File size (bytes): 2206 STIS Filename: opp93013 Title: Packet radio tests, Lake Fryxell File size (bytes): 1666 STIS Filename: opp93014 Title: Addt'l. Earth Fill-McMurdo File size (bytes): 7631 STIS Filename: opp93015 Title: Mgmnt. of wastes-Drifting Stn., Weddell File size (bytes): 3530 STIS Filename: opp93016 Title: ROV Survey of Winter Quarters Bay File size (bytes): 2884 STIS Filename: opp93017 Title: Clean-up of old Palmer File size (bytes): 2665 STIS Filename: opp93018 Title: Steel fuel tanks-Marble Point File size (bytes): 20187 STIS Filename: opp93019 Title: Deck addition at Palmer < File size (bytes): 2694 STIS Filename: opp93020 Title: Palmer boathouse addition < File size (bytes): 2609 STIS Filename: opp93021 Title: Fuel spill reports-Format File size (bytes): 1671 STIS Filename: opp93022 Title: No Household Plants in Antarctica File size (bytes): 4670 STIS Filename: opp93023 Title: Cleaning Palmer's Pond File size (bytes): 4157 STIS Filename: opp93024 Title: McMurdo's Wastewater-dispersion File size (bytes): 3369 STIS Filename: opp93025 Title: Temporary incinerator, McMurdo < File size (bytes): 13475 STIS Filename: opp93026 Title: Site Cleanup of East Base File size (bytes): 2848 STIS Filename: opp93027 Title: Black Island Comm. Upgrade File size (bytes): 13284 STIS Filename: opp93028 Title: All-Terrain Vehicle use at McMurdo File size (bytes): 3759 STIS Filename: opp93029 Title: Supplmnt. EAM to Temp. Incinerator EAM File size (bytes): 52355 STIS Filename: opp93030 Title: Inorganic Tracer Use - Lake Fryxell File size (bytes): 2139 STIS Filename: opp93031 Title: All-terrain vehicle at Lake Bonney File size (bytes): 13206 STIS Filename: opp93032 Title: Final SEIS, U.S. Antarctic Prog. File size (bytes): 16803 STIS Filename: opp93033 Title: Balloon Payload building File size (bytes): 10370 STIS Filename: opp93034 Title: EAM-Weddell Sea Ice Camp File size (bytes): 11717 STIS Filename: opp93035 Title: IEE, accelerated waste mgt, McM < File size (bytes): 94822 STIS Filename: opp93036 Title: Establishmnet of CARA-effects File size (bytes): 1886 STIS Filename: opp93037 Title: Patent Development File size (bytes): 6509 STIS Filename: opp93038 Title: Hydrocarbon Transport File size (bytes): 4565 STIS Filename: opp93039 Title: Palmer Automatic Weather Station File size (bytes): 5685 STIS Filename: opp93040 Title: Liquor Storage Facility -McMurdo File size (bytes): 9258 STIS Filename: opp93041 Title: Potable Water Well-South Pole File size (bytes): 13177 STIS Filename: opp93042 Title: Summer Camp Modules-South File size (bytes): 14105 STIS Filename: opp93043 Title: Stanchion System Upgrade File size (bytes): 10801 STIS Filename: opp93044 Title: Astro Building-South Pole File size (bytes): 13717 STIS Filename: opp93045 Title: Waste containment area-McMurdo File size (bytes): 7319 STIS Filename: opp93046 Title: Waste Food Storage at Fortress Rocks File size (bytes): 8674 STIS Filename: opp93047 Title: Temp. Satellite Earth Station, McMurdo File size (bytes): 7326 STIS Filename: opp93048 Title: Shelter for Seismological Instrmnts. File size (bytes): 5911 STIS Filename: opp93049 Title: Constrctn. of Bird Blind, Palmer File size (bytes): 6003 STIS Filename: opp93050 Title: "STARS" at Black Island Comms. File size (bytes): 9623 STIS Filename: opp93051 Title: Addition to S-40's Field Camp Hut File size (bytes): 7733 STIS Filename: opp93052 Title: Phas II-clean-up of East Base File size (bytes): 12900 STIS Filename: opp93053 Title: Addendum to EAM -Blk. Isld.Comms File size (bytes): 26292 STIS Filename: opp93054 Title: Addendum to Liquor EAM File size (bytes): 7931 STIS Filename: opp93055 Title: Fuel Bladder Replacement-South Pole File size (bytes): 13717 STIS Filename: opp93056 Title: Shelter for radio repeater-Palmer File size (bytes): 8542 STIS Filename: opp93057 Title: Wind energy, Humble Island File size (bytes): 8307 STIS Filename: opp93058 Title: Installation-Lights-McMurdo File size (bytes): 17364 STIS Filename: opp93059 Title: Waste Dairy Product-Disposal-McMurdo File size (bytes): 14251 STIS Filename: opp93060 Title: Airdrop of Fuel-Weddell File size (bytes): 10284 STIS Filename: opp93061 Title: Follow-up to Airdrop of Fuel File size (bytes): 2721 STIS Filename: opp93062 Title: Fuel Removal-Weddell File size (bytes): 22065 STIS Filename: opp93063 Title: Ice wharves at McMurdo < File size (bytes): 43391 STIS Filename: opp93064 Title: Hydroponics Project--South Pole File size (bytes): 16403 STIS Filename: opp93065 Title: Human Waste Handling-Kooyman File size (bytes): 2336 STIS Filename: opp93066 Title: S.Pole Camp Upgrade-2 new modules File size (bytes): 22242 STIS Filename: opp93067 Title: New Traffic Control Tower-South Pole File size (bytes): 11570 STIS Filename: opp93068 Title: Fuel Pumping Station-Palmer File size (bytes): 14124 STIS Filename: opp93069 Title: Soil sample for balloon flight File size (bytes): 9690 STIS Filename: opp93070 Title: Comms. Repeater system-Dry Valleys File size (bytes): 10832 STIS Filename: opp93071 Title: Use of 51Cr by S-035 File size (bytes): 2663 STIS Filename: opp93072 Title: Human Waste-Testa/S-004 File size (bytes): 1823 STIS Filename: opp93073 Title: Improvements to Scott Base Road File size (bytes): 12445 STIS Filename: opp93074 Title: Human Waste Disposal-McMurdo File size (bytes): 20667 STIS Filename: opp93075 Title: Two Day Tanks-McMurdo File size (bytes): 11736 STIS Filename: opp93076 Title: Fuel Cache at Patriot Hills File size (bytes): 10813 STIS Filename: opp93077 Title: Cnsctn. of containment-McMurdo's Tanks File size (bytes): 19014 STIS Filename: opp93078 Title: Hut Point Initiiative-McMurdo File size (bytes): 9510 STIS Filename: opp93079 Title: Replacement of Fuel Cache-South Pole File size (bytes): 13553 STIS Filename: opp93080 Title: Storage Tanks-Marble Point File size (bytes): 20186 STIS Filename: opp93081 Title: Release of dye into McM Wastewater File size (bytes): 15278 STIS Filename: opp93082 Title: South Pole CARA Building File size (bytes): 16098 STIS Filename: opp93083 Title: UV Monitoring Building as an addition File size (bytes): 11013 STIS Filename: opp93084 Title: Demolition of Bldg.56,EBC-McMurdo File size (bytes): 15853 STIS Filename: opp93085 Title: Envnmntl. Assmnt.-Women's Expdtn. File size (bytes): 1568 STIS Filename: opp93086 Title: Reverse Osmosis Unit-McMurdo File size (bytes): 6971 STIS Filename: opp93087 Title: S.Pole Power Upgrade File size (bytes): 11292 STIS Filename: opp93088 Title: Installation of T-306 Antenna File size (bytes): 14834 STIS Filename: opp93089 Title: Replcmnt. of Woodstove-Palmer File size (bytes): 9555 STIS Filename: opp93090 Title: Earth Fill Materials-McMurdo File size (bytes): 27552 STIS Filename: opp93091 Title: Robot Operations, Mt. Erebus File size (bytes): 7687 STIS Filename: opp93092 Title: Bicycles at McMurdo Station File size (bytes): 11036 STIS Filename: opp93093 Title: Rock Splitting-USAP project S-015 File size (bytes): 10116 STIS Filename: opp93094 Title: Waste Staging Area-Fortress Rock File size (bytes): 14868 STIS Filename: opp93095 Title: Sewer Outfall Quay Project-McMurdo File size (bytes): 19585 STIS Filename: opp93096 Title: Fuel Tanks & Berms-McMurdo File size (bytes): 15765 STIS Filename: opp93097 Title: USAP's Mngmnt. of Food Wastes-McMurdo File size (bytes): 94994 STIS Filename: opp93098 Title: Underground Freezer at Lake Bonney File size (bytes): 11463 STIS Filename: opp93099 Title: New Storage Tanks-McMurdo File size (bytes): 19673 STIS Filename: opp93100 Title: Wood Waste Staging Pile-McMurdo File size (bytes): 13100 STIS Filename: opp93101 Title: Automatic Weather Stations File size (bytes): 18449 STIS Filename: opp93102 Title: Blue-ice and snow runways < File size (bytes): 61092 STIS Filename: opp93103 Document Type: Directions Title: Directions, Spring 1993 Issue File size (bytes): 32315 STIS Filename: dir9306 Document Type: General Publication Title: NSF 93-74 Engineering News File size (bytes): 66719 STIS Filename: nsf9374 Document Type: Letter Title: NSF 93-60 Dear Colleague Letter for Jointly funded Cross-Discipl File size (bytes): 6503 STIS Filename: nsf9360 Title: NSF 93-68 - Federal Advanced Materials Processing Program File size (bytes): 12177 STIS Filename: nsf9368 Document Type: Report Title: NSF 93-69 - Summary of NSF Workshop on Research Opportunities in Manufacturing in the Process Industries File size (bytes): 126357 STIS Filename: nsf9369 Title: NSF 93-70 - Beyond National Standards and Goals- Excellence in Math. & Science Ed., K-16 File size (bytes): 342275 STIS Filename: nsf9370 f ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet) or stisinfo@NSF (BITNET). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserv@nsf.gov (Internet) or stisserv@NSF (BITNET). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve nsf9370, the text of your message should be as follows: get nsf9370 Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve nsf9370, you would enter: ftp> get nsf9370 WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "firstop@nsf.gov" (Internet) or "firstop@nsf" (BITNET). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet) or "stis@NSF" (BITNET). From owner-sci-resources@net.bio.net Sun Jul 11 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 12 July 1993 Message-ID: Date: 12 Jul 93 20:27:50 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 172 Approved: sci-resources-moderator@net.bio.net ** NEW DOCUMENTS ON STIS ** Document Type: Antarctic EAM Title: OPP93104 Sea water desalination system, McMurdo File size (bytes): 42071 STIS Filename: opp93104 Document Type: Program Guideline Title: NSF 93-88 Visiting Professorships for Women (VPW) File size (bytes): 33670 STIS Filename: nsf9388 Title: NSF 93-89 The 1994 U.S./Canada Arctic Ocean Section File size (bytes): 13164 STIS Filename: nsf9389 Title: NSF 93-94 - Chemistry Research Instrumentation and Facilities File size (bytes): 48152 STIS Filename: nsf9394 Document Type: Recruit Title: Science Education Administrator (Program Director) File size (bytes): 4877 STIS Filename: vex9323 Title: Science Education Administrator (Program Director) File size (bytes): 4949 STIS Filename: vex9324 Title: Science Education Administrator (Program Director) File size (bytes): 4706 STIS Filename: vex9325 Title: Secretary (Office Automation File size (bytes): 4992 STIS Filename: vgs9374 Title: Secretary (Office Automation) File size (bytes): 5358 STIS Filename: vgs9375 Title: Program Assistant (Office Automation) File size (bytes): 5421 STIS Filename: vgs9376 Title: Auditor File size (bytes): 6336 STIS Filename: vgs9377 Document Type: Report Title: NSF 93-47 - Research Abstracts for Student Presentations File size (bytes): 328 STIS Filename: nsf9347 Also available: nsf9347.wp5 ------------------------------------------------------------------------ ** UPDATES TO EXISTING STIS DOCUMENTS ** Document Type: Phone Book Title: NSF Alphabetical Listing File size (bytes): 91065 STIS Filename: phnalpha Title: NSF Organizational Directory File size (bytes): 95677 STIS Filename: phnorg Document Type: Press Release Title: NSF PR93-43 OUTSTANDING SCIENCE STUDENTS AWARDED NSF MINORITY GRADUATE FELLOWSHIPS File size (bytes): 4242 STIS Filename: pr9343 Title: NSF PR 93-44 NSF, WHITAKER FOUNDATION SEEK RESEARCH IDEAS File size (bytes): 4592 STIS Filename: pr9344 Title: NSF 93-45 BLINDED PHYSICIST, DETERMINED TO CONTINUE NSF-FUNDED RESEARCH, DEVELOPS NEW BRAILLE TECHNOLOGY FOR SCIENCE AND MATH File size (bytes): 4479 STIS Filename: pr9345 Title: NSF PR 93-46 NORMAN HACKERMAN RECEIVES NSB VANNEVAR BUSH AWARD File size (bytes): 4341 STIS Filename: pr9346 Title: NSF PR 93-47 ANTARCTIC FOSSILS GIVE NEW CLUES TO BIRD EVOLUTION File size (bytes): 4476 STIS Filename: pr9347 Title: NSF PR 93-48 SWEEPING EDUCATION REFORM FUNDED FOR FIVE MORE STATES File size (bytes): 5905 STIS Filename: pr9348 Title: NSF PR 93-49 WORKSHOP ON ARCTIC CONTAMINATION HIGHLIGHTS NEED FOR RESEARCH File size (bytes): 5364 STIS Filename: pr9349 Title: NSF PR 93-50 SF SEEKS NOMINATIONS FOR NINETEENTH ALAN T. WATERMAN AWARD File size (bytes): 3353 STIS Filename: pr9350 Title: NSF PR 93-51 NSB REAFFIRMS COMMITMENT TO BASIC RESEARCH File size (bytes): 2232 STIS Filename: pr9351 Title: NSF PR 93-52 LONG-TERM ECOLOGICAL RESEARCH IN THE DESERT SOUTHWEST--HUNDREDS OF PLANTS, BIRDS, INSECTS, AND MAMMALS HAVE BEEN DOCUMENTED IN THIS ARID REGION WHERE MAJOR LIFE ZONES MEET File size (bytes): 7673 STIS Filename: pr9352 Title: NSF PR 93-53 SOUTH POLE RESEARCHERS OBSERVE EARLY STRUCTURE OF THE UNIVERSE File size (bytes): 5846 STIS Filename: pr9353 ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet) or stisinfo@NSF (BITNET). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserv@nsf.gov (Internet) or stisserv@NSF (BITNET). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve pr9353, the text of your message should be as follows: get pr9353 Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve pr9353, you would enter: ftp> get pr9353 WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "firstop@nsf.gov" (Internet) or "firstop@nsf" (BITNET). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet) or "stis@NSF" (BITNET). From owner-sci-resources@net.bio.net Mon Jul 12 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 22, no. 25, pt. 3, 16 July 1993 Message-ID: Date: 13 Jul 93 22:19:26 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 596 Approved: sci-resources-moderator@net.bio.net $$XID RFA CA93034 CA-93-034 P1O1 *************************************** DEVELOPMENTAL RESEARCH IN NATIVE PACIFIC POPULATIONS NIH GUIDE, Volume 22, Number 25, July 16, 1993 RFA: CA-93-034 P.T. 34, FB; K.W. 0715035, 0795003, 0745027 National Cancer Institute Letter of Intent Receipt Date: August 18, 1993 Application Receipt Date: October 20, 1993 PURPOSE The National Cancer Program is mandated to address the unique cancer prevention, early detection, and treatment needs of all populations within the U.S. and its territories. An excerpt from the FY 1992 Committee on Appropriations to the U.S. Department of Health and Human Services stated: "The Committee also urges NCI to expand its efforts to develop an appropriate response to the needs of American Samoans. Access to timely treatment intervention is especially important for this native American population...." (Senate Report No. 102-104, page 86) Therefore, the Division of Cancer Prevention and Control (DCPC) of the National Cancer Institute (NCI) invites applications from various organizations for developmental studies that: (1) assess cancer control need, (2) determine barriers to cancer control, and/or (3) validate intervention methods and assessment instruments in native Pacific populations; i.e., American Samoans, Guamanians (Chamorros), Palauians, and Northern Marianians. This initiative will define the cancer prevention and control needs of native Pacific populations and those of similar ancestry located in the Pacific as well as the U.S. mainland. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Developmental Research in Native Pacific Populations, is related to the priority area of cancer. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic (including U.S. Territorial possessions) public and private, for-profit and non-profit organizations serving native Pacific populations such as universities, public health departments, voluntary organizations, research centers, hospitals, consortia of health providers, units of State and local governments and eligible agencies of the Federal government. Teams of applicants are encouraged. Among a team of applicants, one institution must be proposed as the lead institution to serve as the applicant and to assume responsibility for the conduct and administration of the project. Note that awards will not be made to foreign institutions and that applications from domestic organizations may not include international components. MECHANISM OF SUPPORT The mechanism of support for this RFA will be the National Institutes of Health (NIH) research project grant (R01). Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. In addition to the requirements stated in this RFA, awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement, DHHS Publication No. (OASH) 90-50,000, revised October 1, 1991. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. It is anticipated that four awards will be made at approximately $300,000 total costs per year. FUNDS AVAILABLE Approximately $1.2 million in total costs per year for three years will be set-aside to specifically fund applications that are submitted in response to this RFA. It is anticipated that up to four awards will be made. The total project period of these awards may not exceed three years. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCI, the award of a grant pursuant to this RFA is also contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background The National Cancer Program is mandated to address the unique cancer prevention, early detection, and treatment needs of all populations within the U.S. and its territories. The cancer control objectives for the nation are aimed at (1) reducing the cancer death rates for all Americans and (2) eliminating differentials in cancer rates between population segments. The means to obtain these objectives include the development and implementation of cancer control and prevention strategies directed at the general U.S. population and targeted initiatives directed at minority and medically underserved populations that are differentially affected by cancer. These populations include those who experience high cancer incidence/mortality rates or low survival rates, or who are underserved in terms of cancer prevention and control programs that include the native Pacific populations. The paucity of data on effective cancer prevention and control intervention methods in the target populations reflect both a dearth of such programs and of validated instruments to evaluate their effectiveness. The need for the development of sensitive intervention methods and assessment instruments has to be established in many areas of health (e.g., mental health, cardiovascular diseases) and other sectors (e.g., education). In recent years, the Division of Cancer Prevention and Control (DCPC) has carried out intervention research initiatives directed at the American Indian/Alaska Native, Black, Native Hawaiian, and Hispanic populations. These experiences, combined with information gathered through external working groups and experts in the cancer prevention and control needs of minority and medically underserved populations and extensive conversations with experienced investigators, has clarified the need for Phase I and Phase II cancer control studies for native Pacific populations. It is clear that the concepts of health and healing vary significantly, and this diversity is not captured by a single design, method, or instrument. Studies conducted under this RFA will seek to define cancer prevention and control needs/services of the native Pacific population segments (Phase I). Studies to test ways in which existing intervention methods can be used or adapted for the target populations (Phase II); studies of new methods designed to be sensitive to the needs of the target populations (Phase II); and methodologic research on validation of assessment instruments in target populations (Phase II) are eligible for consideration under the RFA. This "developmental cancer control research" (Phase I and Phase II) is absolutely essential to future development of cancer prevention and control research for native Pacific populations. The following definitions apply to this RFA: 1. Native Pacific Populations -- The term "native Pacific populations" refers to those population segments indigenous to the Pacific region and/or populations of similar ancestry located within the U.S. mainland, such as American Samoan populations. 2. Cancer Control -- Cancer control is defined as the reduction of cancer incidence, morbidity, and mortality through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results. 3. Phases of Cancer Control -- Cancer control research studies are classified in the five phases that represent the orderly progression noted in the above definition: (I) Hypothesis development; (II) Intervention methods development and testing; (III) Controlled intervention trials to establish cause and effect relationships; (IV) Research in defined human populations; and (V) Demonstration and implementation studies. The research of interest in this RFA falls into either Phase I or Phase II studies. Hypothesis development (Phase I) studies should focus on the assessment of cancer prevention and control needs in communities or organizations within native Pacific populations, or studies that identify barriers to cancer prevention and control within these indigenous populations. Methods development and testing studies, Phase II, should focus on: (1) validating the use of existing intervention methods (e.g., dietary modification, health services, tobacco cessation) as applied in the target populations described above; (2) developing and pilot testing unique methods that are sensitive to the needs of the target populations described above, or (3) developing and validating assessment instruments to measure the cancer control related needs of the target populations or for use in evaluating the effectiveness of intervention methods in the target populations. It is the interest of this RFA that the projects should be multidisciplinary in design. Applicable disciplines may include epidemiology, oncology, public health, pathology, health services research, behavioral, and social sciences. The research team should include individuals with knowledge of the culture and language of the native Pacific populations. Because validation and intervention studies may depend on the review of case records, investigators should assure in the application that a mechanism to access pertinent records has been identified. A. Goals and Objectives The goals of this program initiative are to identify cancer control needs, to determine barriers to cancer control, and to validate intervention methods and assessment instruments. The objectives relating to Phases I and II are described below: Phase I Studies 1. Assess cancer prevention and control needs/services in communities with native Pacific populations. 2. Identify barriers to cancer prevention and control in native Pacific population communities. Phase II Studies 1. Validate the use of existing intervention methods (e.g., dietary modification, health services, tobacco cessation) applied in the target populations. 2. Develop and pilot test unique intervention methods sensitive to the needs of the target populations. 3. Develop and validate assessment instruments (e.g., dietary intake, risk factor surveys) to measure the cancer control related needs of the target populations and to evaluate the effectiveness of intervention methods in the target populations. B. Project Approach It is important that applicants describe fully and in detail all aspects of the proposed project in the application, including cancer sites to be studied, the target population for which the research is being conducted, available population data bases, hypotheses to be considered, the planned intervention approaches, methods of assessment and validation, and the overall research design approach to the proposed study. It is essential to select and justify in the application, cancer sites on the basis of the significance in the target population and the potential for reduction of mortality rates. It is also essential that the population for which the study(ies) will be carried out be specified and characterized using population-based estimates of the demographic characteristics of the target population. All collaborative arrangements that are planned should be described in detail, including areas of responsibility, coordinating, decision-making authority, and financial relationships. Letters of commitment from each participating organization should be included in the application. C. Research Plan The applicant should include a detailed protocol outlining the proposed project methods for determining outcome effects. The protocol should detail the research project as conceived and should provide the complete methodological approach to the problem under investigation. The design for the project should provide enough information to determine an adequate "test" of the concepts, whether validation or intervention outcomes. It is important that the design permits statistically valid results to be achieved within the period of award. D. Options in Project Design Applicants must choose from the three types of projects described below: o Type One - Validation study of an existing intervention method for use in a native Pacific population group. o Type Two - Develop and pilot test a "unique" intervention method that is sensitive to the needs of the target population. o Type Three - Develop and validate needs assessment instruments or assessment instruments that could be used to measure effectiveness of cancer control methods in the target population. Applicants must specify which type they have selected in the first line of section 2(a), "Specific Aims", in the application. E. Time Schedule A detailed time schedule should be presented in the application. This schedule is important because it will provide the milestones against which progress will be validated. SPECIAL REQUIREMENTS Awardees should include in the proposed budgets travel to the NCI for up to two persons to attend two meetings of Principal Investigators and NCI program staff to discuss such issues as the validation of stated hypotheses, determination of population characteristics/size relative to the intervention specified, research progress, and results. These meetings will be held approximately three months prior to the scheduled completion of years 01 and 03, respectively. Awardees should anticipate that NCI staff may conduct a site visit as a part of program management in order to assure that projects are proceeding according to the plans specified in the application. This anticipated site visit is not intended to reduce the requirements for the customary detailed progress report in accordance with the instructions appearing in form PHS 2590. STUDY POPULATIONS The targeted population intended under this RFA is the native Pacific populations and those of similar ancestry located in the Pacific as well as the U.S. mainland; i.e., American Samoans, Guamanians (Chamorros), Palauians, and North Marianians. Applicants responding to this RFA are expected to successfully access a significant portion of this population to decrease cancer incidence and mortality, increase cancer survival, and increase the diagnosis of cancers at earlier stages. SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders, and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans [including American Indians or Alaska Natives], Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. LETTER OF INTENT Prospective applicants are asked to submit, by August 18, 1993, a letter of intent that includes a descriptive title of the proposed research, the name and address of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is extremely helpful in planning for the review of applications. It allows NCI staff to estimate the potential review workload and to avoid possible conflict of interest in the review. In addition, if it appears that the potential applicant has misunderstood the objectives of the RFA or opted for an inappropriate funding mechanism, NCI staff will respond to such letters. The NCI would like to emphasize the benefits to the applicant and to staff of having a Principal Investigator submit a letter of intent. The letter establishes communication between the potential applicant and program staff initiating the RFA. Program staff may be able to assist prospective applicants in several areas, i.e., scientific content and objectives of an application, size and focus of a research program, organization of an application, and appropriate use of core components and consultants. The letter of intent is to be sent to: George A. Alexander, M.D. Division of Cancer Prevention and Control National Cancer Institute Executive Plaza North, Room 240 6130 Executive Boulevard Bethesda, MD 20892-4200 Telephone: (301) 496-8589 FAX: (301) 496-8675 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and from the Office of Grants Information Division of Research Grants, National Information of Health, 5333 Westbard Avenue, Room 449, Bethesda, Maryland 20892; telephone 301/594-7248. The RFA label available in the application form PHS 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number should be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed, exact photocopies in one package to the Division of Research Grants at the address below. The photocopies must be clear and single-sided. Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Ms. Toby Friedberg, Referral Officer Division of Extramural Activities National Cancer Institute Westwood Building, Room 838 5333 Westbard Avenue Bethesda, MD 20892 Applications must be received by January 25, 1993. If an application is received after that date, it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application in response to this announcement that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of a substantial revision of an application already reviewed, but the revised application must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Review Procedures Upon receipt, applications will be reviewed (initially) by the DRG for completeness. Incomplete applications will be returned to the applicant without further consideration. Evaluation for responsiveness to the RFA is an NCI program staff function. If an application is judged to be non-responsive, the applicant will be contacted and given an opportunity to withdraw the application or have it considered with other unsolicited applications received by NIH in the next review cycle. Questions concerning responsiveness to the RFA may be directed to NCI program staff listed under INQUIRIES. If the number of applications submitted is large compared to the number of awards to be made, the NCI may conduct a preliminary scientific peer review to eliminate those that are clearly not competitive. The NCI will remove from competition those applications judged to be noncompetitive for award and notify the applicant and institutional business official. Those applications that are complete and responsive will be initially evaluated in accordance with the review criteria stated below for scientific/technical merit by an ad hoc review committee convened by the Division of Extramural Activities, NCI. The second level of review will be provided by the National Cancer Advisory Board. Responsiveness Criteria Applicants must be responsive to this RFA in the sense of being directed towards the attainment of the stated programmatic goals. Five considerations are of paramount importance to this RFA: 1. Descriptions of the cancer problem with justification for the selection of specific cancer site(s) in terms of potential for reduction of mortality rates, cancer control intervention strategy, research method, procedures, analysis plans, and time schedule must be clearly delineated. 2. Studies must be limited to Phase I and/or Phase II only. 3. Assurance of access to a community with characteristics appropriate for the proposed intervention: written documentation must be included. 4. The target population must be a native Pacific population indigenous to the U.S. Pacific territorial region, i.e., American Samoa, Guam, Palau, Northern Marianas; or of similar ancestry located in Hawaii and the U.S. mainland, i.e., American Samoans. 5. Agreements with communities, organizations, agencies, or institutions that are critical to ensure access to appropriate records and to the implementation of the research plan must be included. Review Criteria Each application will be reviewed on its own merit. All applicants must clearly define the target population and geographic location where the program efforts will be demonstrated as well as the project team's ability to access the target population. All applicants should include in the application a succinct discussion of previous relevant efforts and plans to meet the terms of award. Applicants are encouraged to submit and describe the approach that they think would best meet the goals of this RFA and to identify in-kind contributions and/or co-sponsors for specific personnel, activities, and facilities. Each application will be reviewed according to the following criteria: 1. Scientific merit of the research approach, design, and methodology. 2. Scientific and technical significance and originality of the proposed research. 3. Experience (research or clinical or service) and/or competence of the Principal Investigator and staff. 4. Adequacy of time (effort) that the Principal Investigator and staff would devote to the proposed project. 5. Characterization of the native Pacific population to be used (cultural, spiritual or language considerations) in the proposed project. 6. Adequacy of the approaches to produce valid assessment instruments for use in larger community intervention studies for cancer control. 7. Likelihood of intervention (Phase II studies) to be readily accepted and feasible in terms of cost. 8. Potential for generalizability of the findings and adaptability of the intervention approaches and assessment instruments in other communities with similar cancer control problems. 9. Adequacy of the plans for inclusion of women. The ad hoc review group will recommend an appropriate budget for each approved application. AWARD CRITERIA The anticipated date of award is July 1, 1994. Applicants will compete for funding based on the quality and merit of the proposed research study as determined by peer review, availability of funds, and programmatic priorities, as well as geographic location. INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: George A. Alexander, M.D. Division of Cancer Prevention and Control National Cancer Institute Executive Plaza North, Room 240 Bethesda, MD 20892-4200 Telephone: (301) 496-8589 Direct inquiries regarding fiscal issues to: Crystal Elliott National Cancer Institute Executive Plaza South, Room 243 Bethesda, MD 20892 Telephone: (301) 496-7800 Ext. 19 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.399, Cancer Control Science Program. Awards are made under authorization of the Public Health Service Act, Title IV, Part A. (Public Law 78-410, as amended by Public Law 99-158, 42 USC 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. From owner-sci-resources@net.bio.net Mon Jul 12 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 22, no. 25, pt. 2, 16 July 1993 Message-ID: Date: 13 Jul 93 22:18:39 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 534 Approved: sci-resources-moderator@net.bio.net $$XID RFA HS94002 HS-94-002 P1O1 *************************************** MEDICAL TREATMENT EFFECTIVENESS RESEARCH -- PORT-IIs NIH GUIDE, Volume 22, Number 25, July 16, 1993 RFA: HS-94-002 P.T. 34; K.W. 0745027, 0745035, 0745070, 0730050, 0408006 Agency for Health Care Policy and Research Letter of Intent Receipt Date: October 1, 1993 Application Receipt Date: November 16, 1993 PURPOSE This announcement solicits applications to conduct innovative and timely research that will provide convincing evidence for or against the effectiveness and cost effectiveness of alternative clinical interventions for the prevention, diagnosis, treatment, and management of common clinical conditions. The Agency for Health Care Policy and Research (AHCPR) developed this solicitation as part of the Medical Treatment Effectiveness Program (MEDTEP). These awards will constitute a new generation of MEDTEP research and an extension of work carried out by AHCPR's Patient Outcomes Research Teams (PORTs). The new projects, called PORT-IIs, will have potential to make substantial contributions to the improvement of health outcomes. Their results will be relevant to patients, health care providers, and policymakers. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. The AHCPR urges applicants to submit grant applications with relevance to the specific objectives of this initiative. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-004374-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign non-profit organizations, public and private, including universities, clinics, units of State and local governments, non-profit firms, and non-profit foundations. Applications from minority and women investigators are encouraged. MECHANISM OF SUPPORT This RFA will use the research project grant (R01) mechanism. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. This RFA is a one-time solicitation. The total requested project period for applications submitted in response to this RFA may not exceed five years. While the grants under this solicitation may vary in cost, most individual projects are expected to request less than $1 million total direct costs per year. The earliest possible award date will be July 1, 1994. Annual progress reviews by AHCPR and the availability of funds will determine the continuation of grants up to the five year limit. FUNDS AVAILABLE The AHCPR expects to award up to $7 million in Fiscal Year 1994 to support the first year of 5 to 10 studies. The number of awards will be contingent on the availability of funds and the quality of the applications. RESEARCH OBJECTIVES Background and Conceptual Framework Since 1989, AHCPR has made a major investment and major advances in medical effectiveness/patient outcomes research, especially through the set of special, multi-faceted projects known as Patient Outcomes Research Teams (PORTs). This RFA announces the second generation of special projects, PORT-IIs, a pragmatic program that continues to put the patient foremost and to emphasize the policy significance of understanding what health care is most effective. What is new in PORT-IIs is the effort to expand the potential for discovery by encouraging individual customization and creativity in research designs. The individual methods common in PORTs (e.g., meta-analysis and variations studies based on analysis of administrative data) are available for, but not required in, PORT-IIs. PORT-IIs will focus on the establishment of direct linkages between practice and outcomes and on research methods that facilitate direct comparisons of alternative clinical strategies. They are expected to start with carefully formulated research questions and employ research strategies tailored to the selected condition and the population at risk. Emphasis is placed on research designs that can answer convincingly and efficiently questions about which clinical strategies lead to the desired outcomes. Research under AHCPR's Medical Treatment Effectiveness Program is concerned with enhancing the "effectiveness," "cost effectiveness," and "appropriateness," of health care, as defined below. "Effectiveness," as distinct from "efficacy," refers to the outcomes experienced by or observed in patients in routine clinical practice. Effectiveness studies take into account the complexities that result from the many clinical and non-clinical variables that influence practice and outcomes. At a minimum, these include relevant comorbidities, medical history, and adherence to treatment recommendations; relevant demographic, socioeconomic, and cultural characteristics; and patients' values and preferences. They may include differences in clinicians' training, skills, and practice styles. Differences in organizational factors, such as financial incentives and composition of the clinical team, also may be considered as important independent variables. It is expected that the result of this inclusionary approach will be a set of studies the findings of which can be generalized to health care as it is typically received and practiced in the community. The PORT-II's emphasis on the generalizability of findings excludes from consideration, under this RFA, typical "efficacy" studies. A traditional randomized controlled trial, the findings of which relate only to the potential benefits of clinical interventions under ideal circumstances and in patients who meet narrow eligibility criteria would be non-responsive to this RFA. However, the RFA does include clinical trials that are designed to answer effectiveness questions, i.e., questions about outcomes in persons who are representative of those with the condition that is being studied. Such studies are referred to as "effectiveness trials." "Cost-effectiveness" analyses most often compare the direct monetary costs of health care plus the associated indirect costs (e.g., lost work) with the benefits and burdens of the intervention. Applications responsive to this RFA should address questions of cost effectiveness if or when the interventions to be compared are associated with significant differences in cost or significant differences in effect. The MEDTEP concept of "appropriateness" encompasses both clinical and non-clinical dimensions. It includes consideration not only of the fit between the intervention and the objective and technical aspects of the patient's condition, but also consideration as to whether the known risks and costs of the intervention, and the predicted outcomes, are acceptable to individual patients and to the public. In assessing effectiveness, cost effectiveness, and appropriateness, investigators are encouraged to measure outcomes that emphasize the patient's perspective and to consider how patient preferences influence evaluations of the outcomes. In general, outcomes are to include survival, symptom relief, patient-reported quality of life, functional status, satisfaction with care, and costs. Analysis of a broad set of outcomes is desirable, but it is essential that the research address the most significant outcomes for the particular condition under study, whether these are long - or short-term. SPECIAL REQUIREMENTS Topic Selection This RFA accommodates an extremely wide range of clinical subjects. Public interest in health care reform and more cost-effective use of health care resources makes it important that AHCPR focus on questions with significant potential to improve outcomes and/or decrease costs. The AHCPR's authorizing legislation places special emphasis on conditions that are common and costly in the Medicare program. Applicants are expected to present a strong case for their selected topic in a critical literature review. The review should address the clinical and policy significance of the condition, provide evidence of controversy or information gaps regarding current clinical strategies, and support the formulation of the proposed research question(s). The formulation of the problem should reflect understanding of the issues regarding clinical decisionmaking and the translation of study findings into clinical practice. Further, the discussion should satisfy reviewers that the important questions about outcomes can be answered within the proposed grant period. Most PORT-II studies will be condition-specific or technology-specific. Condition-specific studies should focus on an important clinical condition and the most important interventions for its prevention, diagnosis, treatment, and/or management. In addition to clinical problems that are significant in the Medicare population, this announcement includes conditions and technologies that are common and costly in children, adolescents, and adults under age 65. This includes well-defined diseases (e.g., breast cancer, pediatric asthma), as well as symptoms and conditions (e.g., headache, fatigue, obesity). While acute or chronic conditions may be selected, the AHCPR is especially interested in studies of chronic problems and those treated in ambulatory settings. To be responsive to this RFA, the selected condition must meet all of the following MEDTEP criteria: o high incidence or prevalence in the general population or in major population subgroups; o controversy or open questions over the effectiveness and relative effectiveness of available clinical strategies; and o high cost, whether due to the number of people needing care, high cost of care, or high indirect cost. This announcement encompasses studies that compare two or more distinctly different clinical approaches to the prevention, diagnosis, treatment, management, or rehabilitation of common clinical conditions. Examples of responsive studies include comparisons of: medical vs. surgical treatment, radical vs. conservative surgery, psychotherapy vs. pharmacotherapy, or invasive vs. non-invasive screening tests. Other possible comparisons could include care prescribed or provided by different kinds of health care professionals (e.g., physicians, nurses, therapists) and care provided in different settings. If it is not feasible to address all important treatment options in a single study, applicants must identify the specific interventions the study will address and provide justification for these selections. In general, studies that can carry out the most comprehensive assessments of the pertinent clinical strategies will be of greater interest to AHCPR. Methods Investigators are encouraged to design new research strategies, to use new combinations of methods, or to tailor existing methods to their research question(s) so that convincing evidence will be obtained for, or against, the effectiveness of alternative clinical interventions. Research methods that can be employed include, but are not limited to, quasi-experimental designs, case-control studies, cohort studies, effectiveness trials, meta-analyses, cost-effectiveness analyses, decision modeling, and combinations of these methods. Sources of data about patient outcomes can include: new, established, or adapted surveys of patients and providers; clinical registries; and clinical records from practice-based networks, health maintenance organizations, and other health care providers. In many cases, primary data, collected prospectively, may be most appropriate to the questions and methods involved. However, when secondary data will provide adequate information and an efficient means to address the research questions, applicants are encouraged to use such data. For example, administrative data, although they generally lack clinical detail, may be useful in identifying cases and controls, estimating costs, or measuring selected outcomes. The application should be explicit in its strategy for case-finding and its justification that the results will be generalizable to patients cared for in routine clinical practice. The application should also define the strategy for making direct comparisons of alternative treatments. The application should be explicit and detailed in describing the data collection and analysis. In all cases, the methods and data employed must be justified in terms of their potential for answering the effectiveness research questions under study. There should be evidence of adequate attention to relevant characteristics of each of the following: o the patients and persons at risk for the condition, especially characteristics that may affect case-finding, case-definition, and generalizability; o the condition, especially characteristics that affect quality of data and complexity of analysis (e.g., diagnosis is definite vs. equivocal, course is steady vs. sporadic); o the clinical interventions (duration and timing, stability of technology); o the outcomes (e.g., measurability, timing, stability); o the providers (e.g., training, financial incentives, liability concerns, accessibility); o available data and measures; and o the social and cultural context of illness and health care, especially characteristics that affect disease prevalence, health behavior, access to care, and conduct of research. Project Organization To adequately address the clinical and non-clinical dimensions of effectiveness questions, most studies will require multidisciplinary research teams. In all cases, the composition of the team and relative time commitments of each member should be well justified in terms of substantive knowledge, methodological expertise, and experience in conducting or managing related research projects. It is further expected that the team include at least one individual who is actively involved in the type(s) of patient care central to the study and who contributes understanding of how and why clinical decisions are made in routine clinical practice. Applicants are encouraged to take full advantage of opportunities for efficient enhancements of available expertise, data, and other research resources. This might include collaboration with researchers and practitioners outside their own institutions, creative use of existing data, or "piggybacking" on other data collection activities. Another possibility for leveraging research resources is to conduct comparisons of outcomes where existing practice patterns are known to differ (e.g., across care settings, health care systems, or international borders). STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS CONCERNING INCLUSION OF WOMEN AND MINORITIES IN RESEARCH STUDY POPULATIONS The AHCPR requires all applicants for research grants to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder, or condition under study. Special emphasis must be placed on including minorities and women in studies of diseases, disorders, and conditions which disproportionately affect them. This policy applies to males and females of all ages. If women or minorities are excluded or inadequately represented in research, a clear and compelling rationale must be provided. This policy applies to all AHCPR research grants. The AHCPR will not award grants for applications which do not comply. If the application does not contain the required information, it will be returned without review. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Sections 1 to 4 of the Research Plan and summarized in Section 5, Human Subjects (or in the program narrative section of form PHS 5161 for State and local governments). Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, AHCPR recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., American Indians/Alaskan Natives, Asian/Pacific Islanders, Blacks, Hispanics). Where appropriate, the applicant must provide the rationale for studies on single minority population groups. For foreign awards, the policy on inclusion of women applies fully. Since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. Peer reviewers will address specifically whether the applicant's research plan conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed and the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in the priority score assigned to the application. LETTER OF INTENT Prospective applicants are asked to submit by October 1, 1993, a letter of intent that includes a descriptive title of the proposed research; the names, addresses (including institutions), and telephone numbers of the Principal Investigator and other key personnel; and the number and title of this RFA. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains allows AHCPR staff to estimate the potential review workload and to avoid possible conflict of interest in the review. The letter of intent is to be sent to Dr. Richard Greene at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used. (State and local government agencies may use form PHS 5161 and follow those requirements for copy submission.) These forms are available at most institutional offices of sponsored research; the Office of Grant Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301-594-7248; and the Scientific Review Branch, Agency for Health Care Policy and Research, 2101 East Jefferson Street, Suite 602, Rockville, MD 20852, telephone 301-227-8449 (after July 31, telephone 301-594- 1449). The RFA label available in the PHS 398 application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. The completed, signed, original application and four legible copies of form PHS 398 must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** Completed applications must be received by the Division of Research Grants by November 16, 1993. If an application is received after that date, it will be returned to the applicant. One copy, labeled "Advance Copy," must be submitted simultaneously to: Center for Medical Effectiveness Research Agency for Health Care Policy and Research 2101 East Jefferson Street, Suite 605 Rockville, MD 20852 Failure to provide this advance copy will result in the return of the application to the applicant. REVIEW CONSIDERATIONS Applications will be reviewed initially by the Division of Research Grants, NIH, for completeness and by AHCPR program staff for responsiveness to the RFA. Incomplete and unresponsive applications will be returned to applicants without further consideration. Review criteria for AHCPR grant applications are significance and originality from a scientific and technical viewpoint; adequacy of the method; availability of data or proposed plan to collect data required for the project; qualifications and experience of the principal investigator and proposed staff; adequacy of the plan for organizing and carrying out the project; reasonableness of the proposed budget; and adequacy of the facilities and resources available to the applicant. Applications will be evaluated in accordance with the criteria stated above for scientific/technical merit and the special review criteria listed below by an appropriate peer review group. Applications requesting total direct costs in excess of $50,000 may be reviewed by AHCPR's National Advisory Council for Health Care Policy, Research, and Evaluation. Special Review Criteria The major scientific criterion for evaluating applications under this solicitation is the potential for obtaining convincing, new evidence for, or against, the effectiveness of alternative interventions that are significant in preventing, diagnosing, treating, or managing the selected condition. The selected condition must meet the MEDTEP criteria listed above under Topic Selection. Separate consideration is given to the significance of the research question(s). The review committee will independently evaluate each application received in response to this RFA against the following special scientific and technical review criteria: o scientific importance of the clinical topic and particular clinical interventions to be studied, as justified in a review of the literature; o evidence that the proposed research plan can answer the research question(s) within the project period, i.e., that the science base is adequate, data are available or can be obtained, length of follow-up is sufficient; o attention to technical issues in case-definition, case-finding, data collection, and analysis; o quality and adequacy of the proposed data; o justification for focus on specified outcomes; o adequacy of outcome measures, including measurement of costs if applicable; o extent to which research design permits direct comparisons of treatment effectiveness and of cost effectiveness; o evidence of understanding of the issues in clinical decisionmaking and the translation of research findings into clinical practice; o sensitivity to patient heterogeneity and individual preferences; o generalizability of results; o specification of useful findings or products and identification of constituency(ies) for these; o cost effectiveness of research plan; o composition of the research team, including evidence of necessary experience and expertise, and appropriateness of relative time commitments; and o evidence of productive collaborations (e.g., with other institutions, appropriate professional groups, other sources of support). AWARD CRITERIA Applications will compete for available funds with all other applications for this RFA. The following will be considered in making funding decisions: quality of the proposed project as determined by peer review and availability of funds. The earliest anticipated date of award for applications will be July 1, 1994. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Inquiries regarding programmatic issues and the letter of intent may be addressed to: Richard Greene, M.D., Ph.D. Director, Center for Medical Effectiveness Research Agency for Health Care Policy and Research 2101 East Jefferson Street Rockville, MD 20852 Telephone: (301) 227-8485 (through July 31, 1993) or (301) 594-1485 (effective August 1, 1993) Direct inquiries regarding fiscal matters to: Ralph L. Sloat, Grants Management Officer Agency for Health Care Policy and Research 2101 East Jefferson Street Rockville, MD 20852 Telephone: (301) 227-8447 (through July 31, 1993) or (301) 594-1447 (effective August 1, 1993) AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance, No. 93.180. Awards are made under authorization of the Public Health Service Act, Title IX, as amended by Public Laws 101-239 and 102-410, (42 U.S.C. 299-299c-6) and Section 1142 of the Social Security Act (42 U.S.C. 1320b- 12). Awards are administered under the PHS Grants Policy Statement; and Federal Regulations 42 CFR Part 67, Subpart A, and 45 CFR Part 74 (45 CFR Part 92 for State and local governments). This program is not subject to the intergovernmental review requirements of Executive Order 12372. From owner-sci-resources@net.bio.net Mon Jul 12 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 22, no. 25, pt. 1, 16 July 1993 Message-ID: Date: 13 Jul 93 22:17:32 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 1178 Approved: sci-resources-moderator@net.bio.net NOTE: The NIH Guide may be split into more than one mail message to avoid truncation during e-mail distribution. The first message always begins with the RFP/RFA summary sections followed by the appended texts of the full RFP/RFAs. ---------------------------------------------------------------------- $$XID NIHGUIDE 19930716 V22N25 P1O1 ************************************ X-comment: RFAs described: CA-93-034, HS-94-002, ES-93-002 NIH GUIDE - Vol. 22, No. 25 - July 16, 1993 $$INDEX BEGIN ******************************************************* NOTICES $$INDEX N1 ********************************************************** RECRUITMENT OF UNDERREPRESENTED MINORITIES INTO INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARD PROGRAMS National Institutes of Health INDEX: NATIONAL INSTITUTES OF HEALTH $$INDEX N2 ********************************************************** NEW PROPHET SOFTWARE AVAILABLE National Center for Research Resources INDEX: RESEARCH RESOURCES NOTICES OF AVAILABILITY (RFPs AND RFAs) $$INDEX R1 ********************************************************** CLINICAL EVALUATION OF PSYCHOTHERAPEUTIC MEDICATIONS (NIMH-OP-93-0007) National Institute of Mental Health INDEX: MENTAL HEALTH $$INDEX R2 ********************************************************** CORRELATES OF HIV IMMUNE PROTECTION LABORATORY (NIAID-DAIDS-94-12) National Institute of Allergy and Infectious Diseases INDEX: ALLERGY, INFECTIOUS DISEASES $$INDEX R3 10/20/93 ************************************************* DEVELOPMENTAL RESEARCH IN NATIVE PACIFIC POPULATIONS (CA-93-034) National Cancer Institute INDEX: CANCER $$INDEX R4 11/16/93 ************************************************* MEDICAL TREATMENT EFFECTIVENESS RESEARCH -- PORT-IIs (RFA HS-94-002) Agency for Health Care Policy and Research INDEX: HEALTH CARE POLICY, RESEARCH $$INDEX R5 11/24/93 ************************************************* ENVIRONMENTAL HEALTH SCIENCES EDUCATION (RFA ES-93-002) National Institute of Environmental Health Sciences INDEX: ENVIRONMENTAL HEALTH SCIENCES This publication is also available electronically to institutions via BITNET or INTERNET and is on the NIH GOPHER. Alternative access is through the NIH Grant Line using a personal computer (data line 301/402-2221). Contact Dr. John James at 301/594-7270 for details. $$INDEX END ********************************************************* NOTICES $$N1 BEGIN ********************************************************** RECRUITMENT OF UNDERREPRESENTED MINORITIES INTO INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARD PROGRAMS NIH GUIDE, Volume 22, Number 25, July 16, 1993 P.T. 22, 44, FF; K.W. 0720005 National Institutes of Health The purpose of this notice is to clarify the policy and to update previous notices about the recruitment of underrepresented minorities into institutional National Research Service Award (NRSA) (T32) supported research training programs. Previous notices related to this requirement have appeared in the NIH Guide for Grants and Contracts (Vol. 18, No. 20, June 9, 1989 and Vol. 15, No. 4, March 28, 1986). Those notices announced current NIH policy which requires all competing applications for NRSA institutional research training grants to contain a plan for recruitment of individuals from underrepresented minority groups into the research training program. In most respects the policy articulated in this notice remains as described in 1989. All competing applications for institutional research training grants must continue to include a plan to recruit individuals from underrepresented minority groups and competing renewal applications must continue to report accomplishments in recruiting and retaining individuals from underrepresented groups during the previous award period. In addition, all applications will continue to be examined for these components during initial review. The only substantive difference is that review procedures have been updated to permit evaluation of recruitment strategies that have been in place for five or more years in compliance with the NIH requirement. As a consequence, beginning with research training grant applications received for the September 10, 1993 receipt date, the adequacy of the recruitment and retention efforts and the success in identifying and appointing minority trainees during the previous award period will be considered by a peer review panel. In all respects, the NIH remains strongly committed to increasing the participation of individuals from underrepresented minority groups in biomedical and behavioral research. Since the NRSA research training grant program currently supports approximately 14,000 predoctoral and postdoctoral trainees in biomedical and behavioral research, this program is considered an ideal mechanism to accomplish these goals. At the present, time minority groups considered to be underrepresented in biomedical and behavioral sciences include: Alaskan Natives, Blacks, Hispanics, Native Americans, and Pacific Islanders. This policy is implemented at the NIH as described below: Administrative Procedures As announced in 1989, all competing applications for institutional NRSA research training grants must include a plan to recruit minorities and renewal applications must also include a report on the recruitment and retention record during the previous award period. If an application is received without a plan, or without a report on the previous award period, the application will be considered incomplete and will not be reviewed until this information is provided. During initial review, reviewers will first assign a priority score for the overall technical and educational merit of the application. Then, one or more assigned reviewers will discuss the minority recruitment plan and any record of recruitment and retention for evaluation by the review panel. The recruitment components of each application will be judged to be either acceptable or unacceptable. The findings of the review panel will appear in an administrative note in the summary statement for each reviewed application. The administrative note will include a description of the minority recruitment strategies used in the previous award period, the plans for the next award period, and the achievements of the training program in recruiting and retaining underrepresented minority trainees. If the minority recruitment section of the application is judged to be unacceptable, funding will be withheld until a revised plan that addresses the deficiencies is received. Staff within the awarding component, with guidance from the appropriate national advisory board or council, will determine whether or not amended plans and reports submitted after the initial review are acceptable. Acceptable Plans The notice that appeared in the NIH Guide for Grants and Contracts (Vol. 18, No. 20, June 9, 1989) contained a list of strategies that might be used to facilitate minority recruitment. For example, advertisements, posters, flyers, visits to minority institutions, the development of cooperative programs with minority institutions, interactions with scientific and professional societies, appointment of minority faculty and a variety of other suggestions were offered. The minority recruitment efforts that seem to be most successful are those that combine a number of different strategies tailored to the needs of the particular training program. Reviewers will judge the acceptability of the plan, considering the size of the training program, the geographic location, and the availability of minority applicants. For example, more aggressive recruitment efforts may be required in programs where there has traditionally been a shortage of minority applicants. Although institutional efforts to increase the ethnic diversity are important and commendable, they will not be accepted as substitutes for the active involvement of the program director and the participating faculty in recruiting underrepresented minorities into specific training programs. To help locate future minority trainees, the NIH has recently published a booklet that lists the names, addresses, and telephone numbers for all NRSA research training program directors, including directors of Minority Access to Research Careers (MARC) Honors Undergraduate Research Training Grants. The booklet also contains information on Principal Investigators of Minority Biomedical Research Support (MBRS) research grants. This resource booklet will permit training program directors to make contact with individuals who may have knowledge of minorities interested in appointment to a research training grant. Booklets can be obtained by writing to Dr. Walter Schaffer, NIH Research Training and Research Resources Office, Building 31, Room 5B44, Bethesda, MD 20892. Underrepresented minority students should, of course, be recruited from all institutions. Reports of Accomplishments Competing renewal applications for research training grants must include a detailed account of experiences in recruiting individuals from underrepresented groups during the previous award period including information on the types of recruitment strategies used and which types have been successful or unsuccessful. Also, the report should provide information on the racial/ethnic distribution of: (a) students and or postdoctorates in the department(s) relevant to the training grant, (b) individuals who applied for training, (c) individuals who were offered admission, and (d) individuals who were appointed to the research training grant. For those trainees who were appointed to the grant, the report should include information about the duration of training and whether or not those trainees have finished training in good standing. Peer reviewers will carefully examine and evaluate the record of the program in recruiting and retaining underrepresented minority trainees during the previous award period. They will also consider whether or not the experience in recruitment during the previous award period has been incorporated into the formulation of the recruitment plan for the next award period. Information on the recruitment and retention of underrepresented minority trainees appointed during the previous budget period must also be provided in progress reports included in non-competing applications for all institutional research training grants. $$N1 END ************************************************************ $$N2 BEGIN ********************************************************** NEW PROPHET SOFTWARE AVAILABLE NIH GUIDE, Volume 22, Number 25, July 16, 1993 P.T. 34; K.W. 1004017, 1004005, 0710030, 0760053 National Center for Research Resources The Biomedical Research Technology Program, National Center for Research Resources (NCRR), is now making available a new release of its low-cost PROPHET information management, analysis, and visualization package. With a vastly improved graphical user interface, you can choose commands from pull-down menus, provide information through dialogue boxes tailored for each task, and readily invoke a variety of analysis tools. The new graphical interface is a dynamic window environment with full color, multiple fonts, and multi-object screen management. PROPHET can increase research productivity because it runs on powerful networked workstations, and its graphical interface provides easy access to the system's extensive capabilities. The PROPHET software package is fully documented, engineered, and supported by scientific software professionals. PROPHET offers the following features for biomedical scientists: o Spreadsheet-style data entry and organization o Clinical study data management o Statistical and mathematical modeling o Detailed two-dimensional graphs (scatterplots, histograms, bargraphs, and boxplots) o Biological simulation and modeling o Molecular modeling and display o Nucleic acid and protein sequence manipulation, analysis, and display o Developing custom applications via a high-level programming language and debugger o Interfaces to Ingres, SAS, Genbank, and PIR Protein Sequence Database o On-line system with integrated text and graphics o Hotline and electronic mail support Scientists at universities, research centers, hospitals, government laboratories, and commercial facilities use PROPHET in many disciplines including: o Clinical research o Molecular Biology o Biochemistry o Chemistry o Immunology o Biology o Pharmacology o Microbiology o Physiology o Biomedical Engineering o Epidemiology o Oncology PROPHET is currently available on UNIX and ULTRIX workstations with Motif, OpenLook, and DECwindows windowing systems. These workstations include Sun-4, SPARCstation, and DECstation 5000. Additional ports and continuing enhancements are planned. INQUIRIES For further information, contact: Dr. Richard DuBois Biomedical Research Technology Program National Center for Research Resources Westwood Building, Room 8A-15 Bethesda, MD 20892 Telephone: (301) 594-7934 $$N2 END ************************************************************ NOTICES OF AVAILABILITY (RFPs AND RFAs) $$R1 BEGIN NIMH-OP-93-0007 ****************************************** CLINICAL EVALUATION OF PSYCHOTHERAPEUTIC MEDICATIONS NIH GUIDE, Volume 22, Number 25, July 16, 1993 RFP AVAILABLE: NIMH-OP-93-0007 P.T. 34; K.W. 0745060, 0740025, 0755015 National Institute of Mental Health The purpose of this procurement is to conduct Phase I and Phase II clinical trials of compounds to evaluate their utility as new and effective psychotherapeutic medications. The contractor must have the capability to plan the clinical development of an investigational compound, design and develop protocol, provide clinical trial sites, monitor clinical studies to Good Clinical Practice standards, manage data acquisition, and prepare quality written final summary reports in support of a NDA submission. A twenty-eight month cost reimbursement type contract with three one-year options is anticipated. This announcement appeared in the Commerce Business Daily April 29, 1993. Persons who responded to the Commerce Business Daily announcement are already on the mailing list for RFP No. NIMH-OP-93-0007 and are not required to respond to this notice. The RFP is scheduled for issuance on or about July 1, 1993 and will close approximately 60 calendar days thereafter. INQUIRIES All requests must be made in writing or by FAX to: LouEllen M. Rice, Contracting Officer Contracts Management Branch Parklawn Building, Room 7C-18 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-2696 FAX: (301) 443-6885 Telephone requests will not be honored. $$R1 END ************************************************************ $$R2 BEGIN NIAID-DAIDS-94-12 **************************************** CORRELATES OF HIV IMMUNE PROTECTION LABORATORY NIH GUIDE, Volume 22, Number 25, July 16, 1993 RFP AVAILABLE: NIAID-DAIDS-94-12 P.T. National Institute of Allergy and Infectious Diseases The National Institute of Allergy and Infectious Diseases (NIAID), NIH has a requirement for a Correlates of HIV Immune Protection Laboratory that will provide extensive, coordinated, in-depth evaluation of the immunology and/or virology of recipients of acquired immunodeficiency syndrome (AIDS) vaccine(s) who are not protected against HIV-1. Vaccinees or subjects in natural history cohorts who are apparently exposed to, but not infected by, HIV and when available, their infected partners, also will be included in these extensive evaluation studies. Control subjects will include infected placebo recipients and uninfected vaccine responders who may have been exposed to HIV during the same or parallel vaccine studies, recent seroconverters, and HIV-infected subjects with evidence of prolonged asymptomatic periods following infection who have been identified in natural history cohorts. Therefore, this proposed Contract will establish the Correlates of HIV Immune Protection Laboratory, which will provide extensive, in-depth evaluation of the humoral and cellular immune responses of vaccinee and cohort study subjects and controls. In addition, from infected subjects, this laboratory will isolate and characterize the genotype and both the serological and biological phenotype of infecting HIV. This contract is intended to support the NIAID mission of development and clinical testing of AIDS vaccines. It is anticipated that a single contract will be awarded to carry out highly coordinated immunological, virological, and molecular biological assessments. It is further anticipated that a consortium of laboratories with the distinct expertise will be required for the successful completion of the different technical tasks. This is an announcement for an anticipated Request for Proposals (RFP). The issuance of RFP No. NIH-NIAID-DAIDS-94-12 will be on or about August 15, 1993 and proposals will be due by the close of business on November 15, 1993. It is anticipated that one contract will be awarded to carry out highly coordinated immunological, virological, and molecular virological assessments as a result of this solicitation. It is expected that the contract will have a five-year period of performance and a completion type cost- reimbursement contract is anticipated. INQUIRIES Requests for the RFP are to be directed in writing to: Mr. Lawrence Butler Contract Management Branch National Institute of Allergy and Infectious Diseases Solar Building, Room 3C07 6003 Executive Boulevard Bethesda, MD 20892 (use Rockville, Maryland 20852 for overnight mail service) Please provide this office with three self-addressed mailing labels. Telephone inquiries will not be honored and all inquiries must be in writing. A short-form version of the RFP will be provided, which includes the Statement of Work and the Evaluation Criteria to be used for selection of the awardee. All proposals from responsible sources will be considered by the NIAID. This advertisement does not commit the Government to award a contract. No collect calls will be accepted. $$R2 END ************************************************************ $$R3 BEGIN CA-93-034 FULL-TEXT ************************************** DEVELOPMENTAL RESEARCH IN NATIVE PACIFIC POPULATIONS NIH GUIDE, Volume 22, Number 25, July 16, 1993 RFA AVAILABLE: CA-93-034 P.T. 34, FB; K.W. 0715035, 0795003, 0745027 National Cancer Institute Letter of Intent Receipt Date: August 18, 1993 Application Receipt Date: October 20, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES, BELOW. PURPOSE The National Cancer Program is mandated to address the unique cancer prevention, early detection, and treatment needs of all populations within the U.S. and its territories. Therefore, the Special Populations Studies Branch (SPSB) of the Division of Cancer Prevention and Control (DCPC) of the National Cancer Institute (NCI) invites applications from various organizations for developmental studies that: (1) assess cancer control need, (2) determine barriers to cancer control, and/or (3) validate intervention methods and assessment instruments in native Pacific populations; i.e., American Samoans, Guamanians (Chamorros), Palauians, and Northern Marianians. This initiative will define the cancer prevention and control needs of native Pacific populations and those of similar ancestry located in the Pacific as well as the U.S. mainland. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Developmental Research in Native Pacific Populations, is related to the priority area of cancer. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone: 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic (including U.S. Territorial possessions) public and private, for-profit and non-profit organizations serving native Pacific populations such as universities, public health departments, voluntary organizations, research centers, hospitals, consortia of health providers, units of State and local governments and eligible agencies of the Federal government. Teams of applicants are encouraged. Among a team of applicants, one institution must be proposed as the lead institution to serve as the applicant and to assume responsibility for the conduct and administration of the project. Note that awards will not be made to foreign institutions and that applications from domestic organizations may not include international components. MECHANISM OF SUPPORT The mechanism of support for this RFA will be the National Institutes of Health (NIH) research project grant (R01). Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. In addition to the requirements stated in this RFA, awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement, DHHS Publication No. (OASH) 90-50,000, revised October 1, 1991. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. It is anticipated that four awards will be made at approximately $300,000 total costs per year. FUNDS AVAILABLE Approximately $1.2 million in total costs per year for three years will be set-aside to specifically fund applications that are submitted in response to this RFA. It is anticipated that up to four awards will be made. The total project period of these awards may not exceed three years. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCI, the award of a grant pursuant to this RFA is also contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Studies conducted under this RFA will seek to define cancer prevention and control needs/services of the native Pacific population segments (Phase I). Studies to test ways in which existing intervention methods can be used or adapted for the target populations (Phase II); or studies of new methods designed to be sensitive to the needs of the target populations (Phase II); or methodologic research on validation of assessment instruments in target populations (Phase II) are eligible for consideration under the RFA. This "developmental cancer control research" (Phase I and Phase II) is absolutely essential to future development of cancer prevention and control research for native Pacific populations. The following definitions apply for this RFA: Cancer Control -- Cancer control is defined as the reduction of cancer incidence, morbidity, and mortality through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results. Phases of Cancer Control -- Cancer control research studies are classified in the five phases that represent the orderly progression noted in the above definition: (I) Hypothesis development; (II) Intervention methods development and testing; (III) Controlled intervention trials to establish cause and effect relationships; (IV) Research in defined human populations; and (V) Demonstration and implementation studies. The research of interest in this RFA falls into either Phase I or Phase II studies. Hypothesis development (Phase I) studies should focus on the assessment of cancer prevention and control needs in communities or organizations within native Pacific populations or studies that identify barriers to cancer prevention and control within these indigenous populations. Methods development and testing studies, Phase II, should focus on: (1) validating the use of existing intervention methods (e.g., dietary modification, health services, tobacco cessation) applied in the target populations described above; (2) developing and pilot testing unique methods that are sensitive to the needs of the target populations described above; or (3) developing and validating assessment instruments to measure the cancer control related needs of the target populations or for use in evaluating the effectiveness of intervention methods in the target populations. STUDY POPULATIONS The targeted population of this RFA is the native Pacific populations and those of similar ancestry located in the Pacific as well as the U.S. mainland; i.e., American Samoans, Guamanians (Chamorros), Palauians, and North Marianians. Applicants responding to this RFA are expected to successfully access a significant portion of this population to decrease cancer incidence and mortality, increase cancer survival, and increase the diagnosis of cancers at earlier stages. SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by August 18, 1993, a letter of intent that includes a descriptive title of the proposed research; the name, address, and telephone number of the Principal Investigator (PI); the identity of other key personnel and participating institutions; and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains is helpful in planning for the review of applications. It allows NCI staff to estimate the potential review workload and to avoid possible conflict of interest in the review. The letter of intent is to be sent to Dr. George A. Alexander at the address listed under INQUIRIES. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91). These forms are available at most institutional offices of sponsored research and the Office of Grants Information Division of Research Grants, National Institutes of Health, Westwood Building, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301/594-7248. Applications must be received by October 20, 1993. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed (initially) by the Division of Research Grants (DRG) for completeness. Incomplete applications will be returned to the applicant without further consideration. Evaluation for responsiveness to the RFA is an NCI program staff function. If an application is judged to be non-responsive, the applicant will be contacted and given an opportunity to withdraw the application or to have it considered with other unsolicited applications received by NIH in the next review cycle. Questions concerning responsiveness to the RFA may be directed to NCI program staff identified under INQUIRIES. Those applications that are complete and responsive will be initially evaluated in accordance with the review criteria stated within the RFA for scientific/technical merit by an ad hoc review committee convened by the Division of Extramural Activities, NCI. The second level of review will be provided by the National Cancer Advisory Board. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct requests for the RFA and inquiries regarding programmatic issues to: George A. Alexander, M.D. Division of Cancer Prevention and Control National Cancer Institute Executive Plaza North, Room 240 6130 Executive Boulevard Bethesda, MD 20892-4200 Telephone: (301) 496-8589 FAX: (301) 496-8675 Direct inquiries regarding fiscal issues to: Crystal Elliott Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 6130 Executive Boulevard Bethesda, MD 20892 Telephone: (301) 496-7800 Ext. 19 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.399, Cancer Control Science Program. Awards are made under authorization of the Public Health Service Act, Title IV, Part A. (Public Law 78-410, as amended by Public Law 99-158, 42 USC 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R3 END ************************************************************ $$R4 BEGIN HS-94-002 FULL-TEXT ************************************** MEDICAL TREATMENT EFFECTIVENESS RESEARCH -- PORT-IIs NIH GUIDE, Volume 22, Number 25, July 16, 1993 RFA AVAILABLE: HS-94-002 P.T. 34; K.W. 0745027, 0745035, 0745070, 0730050, 0408006 Agency for Health Care Policy and Research Letter of Intent Receipt Date: October 1, 1993 Application Receipt Date: November 16, 1993 THE REQUEST FOR APPLICATION (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES, BELOW. PURPOSE This announcement solicits applications to conduct innovative and timely research that will provide convincing evidence for or against the effectiveness and cost effectiveness of alternative clinical interventions for the prevention, diagnosis, treatment, and management of common clinical conditions. The Agency for Health Care Policy and Research (AHCPR) developed this solicitation as part of the Medical Treatment Effectiveness Program (MEDTEP). These awards will constitute a new generation of MEDTEP research and an extension of work carried out by AHCPR's Patient Outcomes Research Teams (PORTs). The new projects, called PORT-IIs, will have the potential to make substantial contributions to the improvement of health outcomes. Their results will be relevant to patients, health care providers, and policymakers. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. The AHCPR urges applicants to submit grant applications with relevance to the specific objectives of this initiative. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-004374-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign non-profit organizations, public and private, including universities, clinics, units of State and local governments, non-profit firms, and non-profit foundations. Applications from minority and women investigators are encouraged. MECHANISM OF SUPPORT This RFA will use the research project grant (R01) mechanism. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. This RFA is a one-time solicitation. The total requested project period for applications submitted in response to this RFA may not exceed five years. While grants under this solicitation may vary in cost, most individual projects are expected to request less than $1 million total direct costs per year. The earliest possible award date will be July 1, 1994. Annual progress reviews by AHCPR and the availability of funds will determine the continuation of grants up to the five year limit. FUNDS AVAILABLE The AHCPR expects to award up to $7 million in Fiscal Year 1994 to support the first year of 5 to 10 studies. The number of awards will be contingent on the availability of funds and the quality of the applications. RESEARCH OBJECTIVES Background and Conceptual Framework. Since 1989, AHCPR has made a major investment and major advances in medical effectiveness/patient outcomes research, especially through the set of special, multi-faceted projects known as Patient Outcomes Research Teams (PORTs). This RFA announces the second generation of special projects, PORT-IIs, a pragmatic program that continues to put the patient foremost and to emphasize the policy significance of understanding what health care is most effective. PORT-IIs will focus on the establishment of direct linkages between practice and outcomes and on research methods that facilitate direct comparisons of alternative clinical strategies. They should start with carefully formulated research questions and employ research strategies tailored to the selected condition and the population at risk in order to ascertain convincingly and efficiently which clinical strategies lead to the desired outcomes. The AHCPR's Medical Treatment Effectiveness Program is concerned with enhancing the effectiveness, cost effectiveness, and appropriateness of health care. "Effectiveness," as distinct from "efficacy," refers to the outcomes experienced by or observed in patients in routine clinical practice. MEDTEP studies take into account the many clinical and non-clinical variables that influence practice and outcomes. This includes characteristics of patients, clinicians, the health care system, and the social environment. The ability to generalize findings to health care as it is typically received and practiced in the community is emphasized. Typical "efficacy" studies, because their results have limited generalizability, are not responsive to this RFA. The RFA does, however, include clinical trials that are designed to answer effectiveness questions, i.e., questions about outcomes in persons who are representative of those with the condition that is being studied. In assessing effectiveness, cost effectiveness, and appropriateness, investigators are encouraged to measure outcomes that emphasize the patient's perspective and to consider how patient preferences influence evaluations of the outcomes. SPECIAL REQUIREMENTS Topic Selection. This RFA accommodates an extremely wide range of clinical subjects. Greater importance will be placed on questions with significant potential to improve outcomes and/or decrease costs. The formulation of the problem should reflect understanding of the issues regarding clinical decisionmaking and the translation of findings into clinical practice. The important questions about outcomes should be answerable within the proposed grant period. Most PORT-II studies will focus on a particular condition or technology. This includes conditions and technologies that are significant in the Medicare population, adults under age 65, children, or adolescents. It includes well-defined diseases as well as symptoms and conditions (e.g., headache, fatigue, obesity). While acute or chronic conditions may be selected, the AHCPR is especially interested in studies of chronic problems and those treated in ambulatory settings. The selected condition must have all of the following characteristics: high incidence or prevalence in the general population or in major population subgroups; controversy or open questions over the effectiveness and relative effectiveness of available clinical strategies; and high costs. PORT-IIs are expected to compare two or more distinctly different clinical approaches to the prevention, diagnosis, treatment, management, or rehabilitation of common clinical conditions, e.g., comparisons of medical vs. surgical treatment, psychotherapy vs. pharmacotherapy; and care prescribed or provided by different kinds of health care professionals. Methods. Investigators are encouraged to design new research strategies, to use new combinations of methods, or to tailor existing methods to their research question(s) so that convincing evidence will be obtained for, or against, the effectiveness of alternative clinical interventions. Research methods that can be employed include, but are not limited to, quasi-experimental designs, case-control studies, cohort studies, effectiveness trials, meta-analyses, cost-effectiveness analyses, decision modeling, and combinations of these. Sources of data can include: new, established, or adapted surveys of patients and providers; clinical registries; and clinical records from practice-based networks, health maintenance organizations, and other health care providers. Project Organization. To adequately address the clinical and non-clinical dimensions of effectiveness questions, most studies will require multidisciplinary research teams. It is expected that the team include at least one individual who is actively involved in the type(s) of patient care central to the study and who contributes understanding of how and why clinical decisions are made in routine clinical practice. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS CONCERNING INCLUSION OF WOMEN AND MINORITIES IN RESEARCH STUDY POPULATIONS The AHCPR requires applicants to include minorities and women in study populations so that research findings can be of benefit to all persons. If women or minorities are excluded or inadequately represented in research, a clear and compelling rationale must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by October 1, 1993, a letter of intent that includes a descriptive title of the proposed research, the names, addresses (including institutions), and telephone numbers of the Principal Investigator and other key personnel, and the number and title of this RFA. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains allows AHCPR staff to estimate the potential review workload and to avoid possible conflict of interest in the review. The letter of intent is to be sent to Dr. Richard Greene at the address listed under INQUIRIES. APPLICATION PROCEDURES The RFA contains important information for applicants and may be obtained from Dr. Richard Greene at the address listed under INQUIRIES. The application receipt date is November 16, 1993. The research grant application form PHS 398 (rev. 9/91) is to be used. This form is available at most institutional offices of sponsored research and the Office of Grant Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301-594-7248. REVIEW CONSIDERATIONS Applications will be reviewed initially by the Division of Research Grants, NIH, for completeness and by AHCPR program staff for responsiveness to the RFA. Incomplete and unresponsive applications will be returned to applicants without further consideration. Applications will be evaluated in accordance with the criteria stated in the RFA for scientific/ technical merit by an appropriate AHCPR peer review group. Review considerations and special review criteria are listed in the RFA. INQUIRIES Requests for the RFA, inquiries regarding programmatic issues, and the letter of intent may be addressed to: Richard Greene, M.D., Ph.D. Director, Center for Medical Effectiveness Research Agency for Health Care Policy and Research 2101 East Jefferson Street Rockville, MD 20852 Telephone: (301) 227-8485 (through July 31, 1993) or (301) 594-1485 (effective August 1, 1993) Direct inquiries regarding fiscal matters to: Ralph L. Sloat Agency for Health Care Policy and Research 2101 East Jefferson Street Rockville, MD 20852 Telephone: (301) 227-8447 (through July 31, 1993) or (301) 594-1447 (effective August 1, 1993) AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance, No. 93.180. Awards are made under authorization of the Public Health Service Act, Title IX, as amended by Public Laws 101-239 and 102-410, (42 U.S.C. 299-299c-6) and Section 1142 of the Social Security Act (42 U.S.C. 1320b-12). Awards are administered under the PHS Grants Policy Statement; and Federal Regulations 42 CFR Part 67, Subpart A, and 45 CFR Part 74 (45 CFR Part 92 for State and local governments). This program is not subject to the intergovernmental review requirements of Executive Order 12372. $$R4 END ************************************************************ $$R5 BEGIN ES-93-002 FULL-TEXT ************************************** ENVIRONMENTAL HEALTH SCIENCES EDUCATION NIH GUIDE, Volume 22, Number 25, July 16, 1993 RFA AVAILABLE: ES-93-002 P.T. 34; K.W. 0725010, 0502017, 0503016 National Institute of Environmental Health Sciences Letter of Intent Receipt Date: September 20, 1993 Application Receipt Date: November 24, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN THE INQUIRIES, BELOW. PURPOSE Human health and human disease result from three interactive elements: environmental factors, genetic susceptibility, and age. The mission of the National Institute of Environmental Health Sciences (NIEHS) is to reduce the burden of human illness and dysfunction from environmental causes by further understanding each of these elements and how they interrelate. The NIEHS achieves its mission through a multidisciplinary biomedical research program, prevention and intervention efforts, and a communication strategy that encompasses training, education, technology transfer, and community outreach. The ultimate goal of NIEHS activities is to define and understand the mechanism of action of environmental agents on human health and to transfer this knowledge to the public benefit. This RFA is for the development of educational materials that teach basic biologic concepts in grades K-12 using environmental health sciences issues. The intent of this announcement is to promote the development of instructional materials that will increase students' comprehension of basic science concepts and will also enhance students' understanding and interest in environmental health sciences. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Environmental Health Sciences Education, is related to the priority area of environmental health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No.017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Organizations with a scientific or educational mission are eligible to submit applications. Such groups include colleges and universities; state and local education agencies; professional societies; museums; research laboratories; media producers; private foundations and industries; and other public and private education-related organizations, for-profit and non-profit. Applicants are strongly encouraged to form consortia entailing active participation by more than one of these groups. Applicants must include teachers or other school personnel in the planning and evaluation of materials/activities. Only applications that include research scientists, technical writers, and educators will be considered responsive to this RFA. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) Education Project Grant (R25). The project period for applications may not exceed three years, and projects are not renewable. FUNDS AVAILABLE The estimated funds (total costs) available for the first year of support for the entire program is anticipated to be $500,000. The maximum award will be $100,000 in direct costs per year. Indirect costs will be paid at eight percent of direct costs less appropriate exclusions. It is expected that four to six awards will be made. Although this program is provided for in the financial plans of the NIEHS, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. EDUCATION OBJECTIVES This RFA is for the development of environmental health sciences education materials for three major divisions of students, K-4th, 5th-8th, and 9th-12th grades. This RFA will support grants for support of groups of scientists, technical writers, and educators to develop materials for students in any or all of the grade groups that will improve understanding and interest in environmental health sciences. It is essential that this be a collaboration between scientists who are familiar with environmental health sciences issues, technical writers who are knowledgeable about health issues, and educators who are familiar with teaching these grade levels. The ultimate goal of these activities is to foster environmental health sciences education and to improve the understanding of the implications of environmental health sciences for these student groups. It is important to note that proposed projects should focus on the interrelationship between environmental factors and human health. Programs addressing only ecology or only health and biology will be considered unresponsive. The objective of this program is to teach or demonstrate a basic science concept or element by exploring the relationship between a biological process and an environmental factor. The NIEHS recognizes that teachers must be prepared to use the materials developed through this RFA. Therefore, the applicant must include a plan for the dissemination and demonstration of the materials developed at appropriate meetings, such as the National Science Teachers Association national meeting or other comparable meeting. The application should include a plan for the national distribution of the materials developed under this program. Although it may be necessary to validate the materials locally or regionally, applications that are not targeted to the national student population will be considered unresponsive. Because the NIEHS believes there should be a thematic approach to EHS issues throughout the three groups, applications should address the development of materials on an issue that could be infused sequentially into the science curriculum of the three groups. The intent of this RFA is for the development of a sequence of materials in which the student is introduced at the K-4 level to a basic science concept using an environmental health sciences topic. Subsequently, the student would be reintroduced in the 5-8 and 9-12 grades to the same science element, but there would be more depth in the material. This spaced learning approach has been demonstrated to be successful. Applicants must take into account the developing National Science Standards, and specifically address how the materials will be infused into the curriculum of the target populations. Applications submitted under this RFA should focus on basic biology elements and use environmental health sciences topics to teach such elements. Specific examples of the types of activities that may be proposed include, but are not limited to: o Developing innovative materials, techniques, and/or curriculum materials for environmental health sciences areas. The applicant should address in the application how these materials will be infused into the curriculum, how the materials will be tested and evaluated, and the number of students to be impacted after the materials are completed. o Preparation and/or presentation of materials or media programs for environmental health sciences education. Projects will not be supported, however, that are for stand-alone media activities. These must be tied to a program to infuse these materials into an existing curriculum. The development of articles for magazines used in biology, general science, chemistry or other publications used in the three grade groups will be considered responsive to the program. Specific examples of instructional topics/units that may be used to demonstrate basic biological principles are included in the RFA, and applicants should carefully read them. LETTER OF INTENT Prospective applicants are asked to submit, by September 20, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NIEHS staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to Dr. Michael J. Galvin, at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. This form is available at most institutional offices of sponsored research and from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 594-7248. Submit a signed, typewritten original of the application, including the checklist and three signed photocopies in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Dr. Allen Dearry Division of Extramural Research and Training National Institute of Environmental Health Sciences 104 T.W. Alexander Drive P.O. Box 12233 Research Triangle Park, NC 27709 Applications must be received by November 24, 1993. REVIEW CONSIDERATIONS Applications will be administratively reviewed for completeness and responsiveness to this RFA. Applications may be triaged on the basis of relative competitiveness. Those applications judged to be competitive will undergo further merit review. The second level of review will be provided by the National Advisory Environmental Health Sciences Council. Potential applicants are strongly encouraged to consider carefully the specific review criteria listed in the RFA before submitting an application or contacting staff. INQUIRIES The NIEHS welcomes the opportunity to clarify any issues or questions from potential applicants, therefore, written and telephone inquiries concerning this RFA are encouraged. However, potential applicants are expected to have reviewed the material in the RFA before contacting the NIEHS. Direct inquiries regarding programmatic issues, requests for the RFA, and address the letter intent to: Michael J. Galvin, Jr., Ph.D. Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, NC 27709 Telephone: (919) 541-7825 FAX: (919) 541-2843 Direct inquiries regarding fiscal matters to: Mr. David L. Mineo Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, NC 27709 Telephone: (919) 541-1373 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.113 and 93.115. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 43 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. $$R5 END ************************************************************ From owner-sci-resources@net.bio.net Mon Jul 12 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 22, no. 25, pt. 4, 16 July 1993 Message-ID: Date: 13 Jul 93 22:20:21 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 609 Approved: sci-resources-moderator@net.bio.net Received: from jhuvm.hcf.jhu.edu by net.bio.net (5.65/IG-2.0) with SMTP id AA11463; Tue, 13 Jul 93 12:01:10 -0700 Message-Id: <9307131901.AA11463@net.bio.net> Received: from JHUVM.HCF.JHU.EDU by JHUVM.HCF.JHU.EDU (IBM VM SMTP V2R2) with BSMTP id 8869; Tue, 13 Jul 93 14:56:23 EDT Received: from JHUVM.HCF.JHU.EDU (NJE origin LISTSERV@JHUVM) by JHUVM.HCF.JHU.EDU (LMail V1.1d/1.7f) with BSMTP id 8868; Tue, 13 Jul 1993 14:54:46 -0400 Date: Tue, 13 Jul 1993 14:50:10 EDT Sender: NIH Guide Primary Distribution From: Becky Duvall Subject: NIH GUIDE - RFA ES-93-002 - V22(25) 07/16/93 To: Multiple recipients of list NIHGDE-L